A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
Status:
Withdrawn
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the overall response rate of Vermurafenib when administered
orally to patients with relapsed or refractory multiple myeloma.